Review illuminates tau protein's dual nature in brain health, disease and emerging psychiatric connections

A review published in Genomic Psychiatry by Dr. Peng Lei and colleagues presents a sweeping synthesis of tau protein research ...
Nasdaq

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...
Yahoo Finance

New Data Presented at AD/PD™ 2023 Show Biogen’s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer’s Disease

The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regions Phase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau ...
Morningstar

Biogen's BIIB080 Gets FDA Fast-Track Designation in Alzheimer's Disease

Biogen has won a U.S. Food and Drug Administration fast-track designation for its investigational BIIB080 therapy for the treatment of Alzheimer's disease. Biogen on Wednesday said BIIB080 is the ...
EurekAlert!

Multi‑target disease‑modifying strategies for Alzheimer’s disease: guided by a comprehensive biomarker framework

Alzheimer’s disease (AD) imposes a substantial clinical and societal burden, yet currently approved symptomatic therapies do ...
Business Insider

New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease

CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its partner Biogen presented new Phase 1b clinical data showing that IONIS-MAPT Rx ...
manilatimes

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...